Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, open-label, multi-center, dose-escalation and dose-expansion study to evaluate the safety and tolerability of mRNA 5671 both as a monotherapy and in combination with KEYTRUDA

Trial Profile

A phase 1, open-label, multi-center, dose-escalation and dose-expansion study to evaluate the safety and tolerability of mRNA 5671 both as a monotherapy and in combination with KEYTRUDA

Planning
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs MRNA 5671 (Primary) ; Pembrolizumab
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 16 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top